[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Federal State Budgetary Scientific Institution \\\"Federal Research Centre of Nutrition, Biotechnology\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":144},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,81,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100602307","the-influence-of-specialized-food-products-based-on-ice-cream-on-esophageal-motility-100602307",false,"NCT07121803","The Influence of Specialized Food Products Based on Ice-Cream on Esophageal Motility","Analysis of Effects of Specialized Food Products Based on Ice-Cream on Esophageal Motility","MICE","Inclusion Criteria:\n\n* willingness to participate based on signed written informed consent;\n* controlled glycemia. If stable glycemia is achieved on treatment, the following requirements should be met:\n* no qualitative changes in treatment within 6 months before enrollment (i.e., the introduction of a new antidiabetic therapy);\n* doses of anti-diabetic medications should be stable for 6 month in patients who receive metformin, gliptins, sulfonylureas, sodium\u002Fglucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 agonists (GLP-1) or insulin.\n* no new medications during participation in the study\n\nExclusion Criteria:\n\n* Pregnancy and breastfeeding;\n* Liver cirrhosis based on liver histology, or liver stiffness measurement (LSM \\> or = 14 kPa by Fibroscan), or APRI \\> or= 1; or BARD score \\> or = 2.\n* Diarrhea of any type (watery stool more than 3 times a day).\n* Chronic heart failure (I-IV class by NYHA).\n* Past major abdominal or chest surgery, including bariatric procedures and fundoplication (except appendectomy or cholecystectomy performed more than a year before enrollment).\n* Achalasia and esophago-gastric junction outflow obstruction\n* Major esophageal motility disorders according to Chicago IV classification.\n* Clinically relevant acute cardiovascular event within 6 months prior to screening.\n* Uncontrolled arterial hypertension despite optimal anti-hypertensive therapy.\n* Diabetes mellitus type 1.\n* The level of glycated hemoglobin \\[HbA1c\\] \\>9.0%.\n* Hypersensitivity to the studied product or any of its components, including lactose intolerance.\n* The intake of any pharmaceutical agents with known influence on esophageal motility (including, but not limited to: beta-blockers, calcium channel blockers, m-cholinoblockers, myorelaxants, antidepressants, tranquilizers, prokinetic agents)\n* Any medical conditions that may significantly affect life expectancy, including known cancers;\n* Any clinically significant immunological, endocrine, hematological, gastrointestinal, neurological, tumor or psychiatric diseases;\n* Mental instability or incapacity, which may impact the ability to give informed consent, take part in the study, or affect the ability to comply with the requirements of the study protocol;\n* Inability to tolerate high-resolution esophageal manometry without sedation, at least in part.",true,"ALL","18 Years","80 Years",{"count":22,"type":23},30,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study aims to assess the influence of specialized products based on ice cream on esophageal motility",[29,30],"Ineffective Esophageal Motility","GERD (Gastroesophageal Reflux Disease)",[32,33,34,35,36,37],"Esophageal motility","Specialized foods","icecream","esophagus","motility","high-resolution esophageal manometry","RECRUITING","2025-08-07",{"date":41,"type":42},"2025-08-14","ACTUAL",{"date":44,"type":42},"2025-07-01",{"date":46,"type":23},"2025-12-31",{"name":48,"class":49},"Federal State Budgetary Scientific Institution \"Federal Research Centre of Nutrition, Biotechnology","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":24,"phases":61,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100571978","assessment-of-tolerability-of-specialized-food-products-made-out-of-vegetable-protein-and-their-influence-on-lipid-profile-in-patients-with-non-alcoholic-fatty-liver-disease-100571978","NCT06727279","Assessment of Tolerability of Specialized Food Products Made Out of Vegetable Protein and Their Influence on Lipid Profile in Patients With Non-alcoholic Fatty Liver Disease","Assessment of Tolerability of Specialized Foods of Vegetable Proteins and Their Influence on Lipid Profile in Patients With Non-alcoholic Fatty Liver Disease","Inclusion Criteria:\n\n* Willingness to participate;\n* Confirmed diagnosis of non-alcoholic fatty liver disease based on EASL guidelines.\n\nExclusion Criteria:\n\n* Pregnancy and breastfeeding;\n* excessive alcohol intake (\\>20 g\u002Fday women and \\>30 g\u002Fday men)\n* Liver cirrhosis based on liver histology, or liver stiffness measurement (LSM \\> or =14 kPa by Fibroscan), or APRI \\> or= 1; or BARD score \\> or = 2.\n* Chronic heart failure (I-IV class by NYHA).\n* Past bariatric surgery.\n* Clinically relevant acute cardiovascular event within 6 months prior to screening.\n* Uncontrolled arterial hypertension despite optimal anti-hypertensive therapy.\n* Diabetes mellitus type 1.\n* Serum glycated hemoglobin \\[HbA1c\\] concentrations \\>9.0%.\n* Hypersensitivity to the studied product or any of its components.\n* The intake of any medications that may affect the absorption, distribution, metabolism or excretion of investigational products or may lead to the induction or inhibition of microsomal enzymes (for example, indomethacin) - from the moment of randomization to the end of treatment.\n* Any medical conditions that may significantly affect life expectancy, including known cancers;\n* Any clinically significant immunological, endocrine, haematological, gastrointestinal, neurological or psychiatric diseases;\n* Mental instability or incapacity, which may impact the ability to give informed consent, take part in the study, or affect the ability to comply with study protocol requirements.\n* Positive test for to human immunodeficiency virus antibodies .\n* Aspartate aminotransferase (AST) and\u002For ALT \\>10 x upper normal limits.\n* conjugated bilirubin \\> 26 mcmol\u002Fl (patients with Gilbert's disease are allowed to the study).\n* International normalized ratio \\>1.40.\n* Platelet count \\\u003C100 x10\\^9\u002FL due related to portal hypertension.\n* Clinically relevant renal dysfunction, including nephrotic syndrome, chronic kidney disease (determined based on the estimated glomerular filtration rate \\[eGFR\\] less than 60 ml\u002Fmin\u002F1.73 m\\^2).","75 Years",{"count":60,"type":23},50,[26],"To this single-centre randomized controlled comparative study it is planned to enroll 50 patients with non-alcoholic fatty liver disease. All these subjects will receive standard isocaloric diet for 14 days. Subjects of the main group will receive vegetable protein-and-fat cutlet or schnitzel insted of the same amount of standard (animal meat based) cutlet or schnitzel. Subjects of the control group will receive standard diet, with cutlets or schnitzels made of animal meat. It is planned to make repeated measurements of serum lipid profile and assess general well-being and tolerability of newly developed product compared to regular meal",[64],"Non-alcoholic Fatty Liver Disease NAFLD",[66,67,68,69,70,71],"non-alcoholic fatty liver disease","vegetable protein","specialized foods","plant-based meat analogs","meat substitutes","tolerability","NOT_YET_RECRUITING","2025-08-01",{"date":75,"type":42},"2025-08-03",{"date":77,"type":23},"2025-09-15",{"date":79,"type":23},"2026-02-28",{"name":48,"class":49},{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":88,"minAge":19,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":24,"phases":92,"briefSummary":94,"conditions":95,"keywords":99,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},"100404550","phase-3-efficacy-of-conservative-treatment-of-functional-defecatory-disorders-in-females-with-pelvic-organ-prolapse-100404550","NCT04547816","Efficacy of Conservative Treatment of Functional Defecatory Disorders in Females With Pelvic Organ Prolapse","Evaluation of Complex (Physical Therapy and Diet) Treatment of Functional Defecatory Disorders in Females With Pelvic Organ Prolapse","Inclusion Criteria:\n\n* Willingness to participate (signed informed consent form)\n* Females with rectocele I-II grade or rectocele I-II grade and internal rectal invagination and functional defecatory disorders (per Rome IV guidelines) confirmed on the basis of complex examination including high-resolution anorectal manometry\n\nExclusion Criteria:\n\n* rectocele III grade;\n* internal genitals prolapse;\n* history of abdominal or pelvic surgery that may impact bowel motility (excluding non-complicated appendectomy or laparoscopic cholecystectomy);\n* gynecological surgery that may influence sensory or reservoir function of rectum;\n* history of major cardiovascular events, or presence of current conditions that in case of participation of the patient in the study may put her at risk of exacerbation or complication;\n* start of any new concomitant medication with mechanisms of action that influence rectal motility, sensory function, muscle tone and\u002For contractility\n* inability to understand and\u002For follow the instructions to perform all the procedures required per protocol\n* general condition of the patient that make her ineligible by the discretion of the investigator","FEMALE","70 Years",{"count":91,"type":23},100,[93],"PHASE3","This study is planned to evaluate the efficacy of complex conservative treatment (including tibial neuromodulation, biofeedback therapy, special pelvic floor training and diet modification) in women with pelvic organ prolapse",[96,97,98],"Pelvic Floor Prolapse","Functional Constipation","Rectocele",[100,101,102,103,104,105,106],"pelvic floor prolapse","conservative treatment","functional disorders of defecation","rectocele","diet modification","biofeedback therapy","tibial neuromodulation",{"date":75,"type":42},{"date":109,"type":42},"2020-07-01",{"date":111,"type":23},"2026-05-31",{"name":48,"class":49},2,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":120,"targetDuration":4,"studyType":24,"phases":122,"briefSummary":123,"conditions":124,"keywords":131,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":50},"100382135","real-life-study-of-changes-of-gastroesophageal-reflux-disease-manifestations-due-to-behavioural-and-diet-adherence-100382135","NCT04255693","Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adherence","Inclusion Criteria:\n\n* willingness to participate (based on the signed informed consent form);\n* presence of gastroesophageal reflux disease, based on the following: a) typical symptoms, like heartburn and\u002For regurgitation (for primary selection, symptoms should be present at least weekly, be actual for at least 3 months prior to the enrolment, and the patient should report the history of symptoms which lasts for at least 6 months); b) previous response to the intake of proton pump inhibitors; c) data of 24-hours oesophageal pH-impedance monitoring with detected pathological gastroesophageal reflux according to the Lyon consensus definitions;\n\nExclusion Criteria:\n\n* pregnant or breast-feeding females;\n* abdominal or chest surgery (except appendectomy or cholecystectomy in case they are not followed by adhesive disease of the abdominal organs);\n* constant use of non-steroidal anti-inflammatory agents (NSAIDs), sporadic use of NSAIDs will be allowed in case the course of treatment was discontinued at least 2 weeks prior to the enrolment, in case that constant use of NSAIDs happen to be necessary after the enrolment, the patients may continue in the study but doses, frequency and duration of treatment should be carefully documented;\n* history or current evidence of cancer of any aetiology and location besides skin cancer in situ successfully treated before the enrolment;\n* severe patient's conditions which may lead to misinterpretation of data, or in case of patient's enrolment may put him at risk of exacerbation of co-morbid conditions, or in cases when on discretion of the investigator patient's condition would not allow him to complete the course of the observation. These conditions include, but not limited to: heart failure (class III-IV by NYHA), uncontrolled hypertension, severe neurological disorders, decompensated liver cirrhosis (Child-Pugh B or C), severe depression or other psychological disorders;\n* the patient may stop his participation in the study at any time by informing the site personal about his\u002Fher decision to withdraw the consent.",{"count":121,"type":23},150,[26],"This study is aimed to investigate the role of long-term diet adherence on manifestations of gastroesophageal reflux disease",[125,126,127,128,129,130],"Gastroesophageal Reflux Disease","GERD","Gastroesophageal Erosion","Erosive Esophagitis","Non-erosive Reflux Disease","Non-Erosive Gastro-Esophageal Reflux Disease",[126,132,133,134,135,136,137],"NERD","erosive esophagitis","diet","food","adherence","influence",{"date":75,"type":42},{"date":140,"type":42},"2020-01-31",{"date":142,"type":23},"2027-12-31",{"name":48,"class":49},""]